Pfizer profits dip on lower Paxlovid sales
Sales of Paxlovid slid 75 percent amid lower Covid-19 infections and reduced government purchases of the medication.
But Pfizer scored higher revenues for its Covid-19 vaccine, along with some other products, including the heart medication Vyndaqel and the cancer drug Padcev.
Profits in the first quarter fell five percent to $3.0 billion, while revenues dropped eight percent to $13.7 billion.
Pfizer Chief Executive Albert Bourla said the company's discontinuation earlier this month of the Danuglipron obesity drug was the right call after a participant in a trial experienced a liver injury that cleared up after the treatment was stopped.
Pfizer is developing other medications in the obesity and related areas and could pursue "external opportunities" such as partnerships or acquisitions, Bourla said.
Pfizer is also working on treatments for a number of other ailments, including bladder cancer and multiple myeloma, Bourla said.
"We are on track for a strong year of anticipated pipeline catalysts," he said.
The drugmaker maintained its full-year sales forecast of between $61-64 billion. In 2024, Pfizer's revenues were $63.6 billion.
The projection "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time," Pfizer said.
Pfizer said it is on track to deliver $4.5 billion in cost savings through the end of 2025. It also is implementing a reorganization of its research and development, and a manufacturing "optimization" program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
3 days ago
- Euronews
EU long-term budget: Is health funding on the chopping block?
Emerging priorities such as defence and competitiveness are increasingly drawing resources away from other sectors, raising concerns that health – a key focus of the previous EU mandate – may pay the highest price in the upcoming long-term EU budget. The European Commission is expected to unveil its proposal for the next seven-year budget in July. However, early leaks and mounting speculation suggest that the dedicated health fund could be merged with broader funding instruments, or potentially scrapped altogether. Although health policy is primarily the responsibility of national governments, EU member states allocated €5.3 billion for health through the EU4Health programme in response to the COVID-19 pandemic. This marked the first time a standalone health budget was created at the EU level. Prior to this, EU health initiatives operated with much smaller resources: The health programme for 2014–2020 had a total budget of just €450 million, significantly less than EU4Health. Since its launch, EU4Health has financed a range of initiatives, such as a recent €1.3 million project to address the nursing shortage across Europe by promoting the profession in countries most affected. Yet many fear that the programme will not survive the next programming cycle. Even some EU officials have hinted that EU4Health may have been a one-time measure. Lawmakers have raised alarms about the potential disappearance of EU4Health and its impact on flagship initiatives from the previous term, such as the Beating Cancer Plan. Croatian MEP Tomislav Sokol pointed out the importance of maintaining a dedicated health budget since health has become one of the most important topics in the EU after the pandemic. For this reason, the EU has opted to create a separate health programme within the bloc's budget to support initiatives like the EU health data space and the European reference networks. 'If we're not able to protect this, I'm afraid this will all be diluted and absorbed by some other big funds in the budget, and we will lose this focus on healthcare that we have now,' he told Euronews. Sokol also cited newer priorities like the Critical Medicines Act, arguing that they, too, will require substantial EU funding. "Of course, healthcare remains largely a national responsibility, but EU support is needed to create a level playing field across member states," he added. Concerns over future health investment stem in part from recent budget reallocations. In February 2024, approximately €1 billion was redirected from EU4Health to help finance an aid package for Ukraine. The looming cuts are causing anxiety in the health sector. The PHSSR – a coalition of academics, policymakers, and politicians working on sustainable health systems – highlighted the need for continued investment in a recent report ahead of the Commission's proposal. In an interview with Euronews, AstraZeneca senior vice-president Greg Rossi, who participated in the PHSSR, stressed that Europe risks falling behind in life sciences. "We're seeing massive innovation and opportunity in improving health outcomes. My area, cancer, has seen extraordinary advances in the last 10 to 15 years. But Europe is losing ground," he said, adding that research and development funding has declined, with clinical trials increasingly moving out of Europe. He warned that, without specific health investment initiatives like a dedicated EU health funding, access to innovation will worsen, health outcomes will deteriorate, and Europe's competitive edge will erode. 'Health is an investment to be made, not a cost to be managed. And if we do so, we'll improve the health and the wealth of our countries,' he said. The European Commission is preparing a comprehensive overhaul of the its long-term budget, also known as Multiannual Financial Framework (MFF) post-2027. The aim is to make it simpler, more effective, and more aligned with evolving policy priorities. Currently, the MFF stands at around €1.2 trillion – roughly 1% of the EU's GDP. Commission President Ursula von der Leyen is considering a major restructuring of the MFF for 2028–2034, possibly moving away from the current system of over 50 EU-level programmes. Budget Commissioner Piotr Serafin previously indicated that the next budget proposal will focus on "fewer, more focused programmes" and a more strategic, ambitious framework. The European Commission's proposal, expected in mid-July, will offer the first concrete signal of what lies ahead for health funding in the EU.
France 24
3 days ago
- France 24
Germany's BioNTech to buy CureVac to boost cancer research
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies". Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells. While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases. BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases. "This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin. It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said. Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof". BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals. Both companies are listed on the Nasdaq Composite Index. They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world. But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results. In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
Euronews
3 days ago
- Euronews
Number of women in top jobs drops third year in row, WEF report says
The number of women hired to senior leadership positions has slowed for a third consecutive year, according to the World Economic Forum's Global Gender Gap Report published on Thursday. The report, which covers 148 economies, says that despite women representing 41.2% of the global workforce, only 28.8% of them reach senior leadership roles. Between 2015 and 2024, the share of women in top management rose from 25.7% to 28.1%, but progress has slowed post-2022. "In many sectors, top-level gains are outpacing mid-level promotions, risking the sustainability of balanced talent pipelines. As cross-industry experience rises, particularly among women, nonlinear career paths are becoming more common," the report added. Overall, the global gender gap has narrowed to 68.8%, the most significant improvement since the COVID-19 pandemic. But even at this rate, full parity is still 123 years away, the data suggested. Iceland maintains its position as the world's most gender-equal economy for the 16th year in a row, with 92.6% of its gender gap closed. Finland (87.9%), Norway (86.3%), the UK (83.8%) and New Zealand (82.7%) are also in the top five. Saadia Zahidi, a Managing Director at the World Economic Forum, said that "economies that have made decisive progress towards parity are positioning themselves for stronger, more innovative and more resilient economic progress." According to data fed into the report by global job website LinkedIn, which has 1 billion members, shutting women out of leadership roles has economic consequences. At the same time, AI is reshaping the world of work and is demanding new skills from business leaders. LinkedIn data suggests that women are 20% more likely to have varied careers, where they develop skills that mean they are now uniquely positioned to navigate, and lead in, the AI economy. Sue Duke, Global Head of Public Policy at LinkedIn, said: "As the global economy is transformed, especially by AI, women must be empowered to deploy the skills and expertise they've developed over the course of their flexible careers." Ukraine and Russia carried out another exchange of prisoners of war on Thursday, based on the Istanbul deal of 2 June. Ukrainian President Volodymyr Zelenskyy said that the latest swap focused on "severely wounded and seriously ill warriors." Ukraine's Coordination Headquarters for the Treatment of the POW issued a statement, saying "this is part of a major exchange that continues in phases." "These soldiers require urgent medical care and will receive full assistance, including psychological rehabilitation and financial compensation for their time in captivity," the coordination HQ said. Kyiv is not revealing how many Ukrainian defenders have been exchanged at each stage. Ukrainian authorities are expected to release this information once the exchange is completed. Kyiv announced that many of the severely injured soldiers who had returned home on Thursday had served in combat operations across Donetsk, Luhansk, Kharkiv, Kherson and Zaporizhzhia regions. Some of the returned soldiers have been considered "missing" while many have been in Russian captivity for over three years. Kyiv and Moscow have been carrying out prisoner-of-war swaps for the last couple of days. During the Istanbul talks, the sides have agreed to exchange young soldiers under 25 and the severely injured and sick POWs. They have also agreed to repatriate the bodies of the soldiers. On Wednesday, Ukraine said it brought back the bodies of 1,212 fallen defenders. The repatriation was carried out through a coordinated effort involving the Security Service of Ukraine (SBU), the Armed Forces, the Interior Ministry, the Ombudsman's Office, the State Emergency Service, and other national security and defence institutions. The International Committee of the Red Cross also supported the operation. Officials emphasised that investigative and forensic teams from the Interior Ministry and the Health Ministry are working to identify the bodies in the shortest possible time. Vladimir Medinsky, aide to Russian President Vladimir Putin and the head of the Russian delegation at the Istanbul talks, claimed that Ukraine released the remains of 27 Russian service members. The Ukrainian side did not disclose how many Russian bodies were handed over to Moscow. After the meeting in Turkey on 2 June, Medinsky said that Russia would transfer 6,000 bodies of Ukrainian soldiers and officers.
